Want to see HNGE full AI Analyst Report?
HNGE Stock Chart & Stats
$74.31
$1.40(1.88%)
At close: 4:00 PM EDT
$74.31
$1.40(1.88%)
Day’s Range― - ―
52-Week Range$30.08 - $91.50
Previous Close$36.79
Volume368.85K
Average Volume (3M)2.05M
Market Cap
$5.75B
Enterprise Value$3.07K
Total Cash (Recent Filing)$317.31M
Total Debt (Recent Filing)$6.97M
Price to Earnings (P/E)―
Beta1.52
Next Earnings
Aug 04, 2026EPS Estimate
0.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.58
Shares Outstanding54,655,926
10 Day Avg. Volume1,732,427
30 Day Avg. Volume2,053,901
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)9.72
Price to Sales (P/S)6.26
P/FCF Ratio21.54
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$87.64Price Target Upside17.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)2.59
Revenue Forecast (FY)$822.16M
Bulls Say, Bears Say
Bulls Say
Cash GenerationThe company’s operating cash flow turned sharply positive and free cash flow surged in 2025, demonstrating the business can generate real cash from operations. Durable FCF reduces refinancing risk, funds reinvestment and buybacks, and provides optionality for product investment or M&A even if GAAP earnings remain volatile.
Balance-sheet StrengthConservative leverage and a growing asset base give the company financial flexibility to scale operations, fund device distribution and marketing, and withstand macro shocks. Low debt enhances capacity for strategic capital allocation (reinvestment, M&A, or buybacks) without urgent refinancing pressure.
Product & Commercial ExpansionFDA clearance and rapid client uptake of the migraine program materially expand the addressable market beyond MSK care and validate product efficacy. Combined with growing provider footprint and engagement-based pricing adoption, this strengthens competitive positioning and recurring revenue potential over the medium term.
Bears Say
Earnings VolatilityA dramatic swing to a very large accounting loss undermines earnings quality and makes forward margin normalization uncertain. Large non‑cash charges or one-offs can recur or obscure unit economics, complicating forecasting, executive incentive alignment, and investor confidence despite strong cash flow metrics.
Device Cost PressureScaling device distribution introduces persistent cost pressure that can erode gross margins unless offset by higher yields or care-team efficiency gains. Given devices are integral to core offerings, sustained unit cost increases represent a structural margin risk as the company expands programs like migraine care.
Seasonal Booking ConcentrationHeavy concentration of bookings late in the year creates predictable timing risk and lumpy revenue recognition, complicating capacity planning and working-capital management. Over multiple cycles this seasonality can amplify downside in years with weaker year‑end sales and slow predictable growth cadence.
Hinge Health, Inc. Class A News
HNGE FAQ
What was Hinge Health, Inc. Class A’s price range in the past 12 months?
Hinge Health, Inc. Class A lowest stock price was $30.08 and its highest was $91.50 in the past 12 months.
What is Hinge Health, Inc. Class A’s market cap?
Hinge Health, Inc. Class A’s market cap is $5.75B.
When is Hinge Health, Inc. Class A’s upcoming earnings report date?
Hinge Health, Inc. Class A’s upcoming earnings report date is Aug 04, 2026 which is in 6 days.
How were Hinge Health, Inc. Class A’s earnings last quarter?
Hinge Health, Inc. Class A released its earnings results on May 05, 2026. The company reported $0.45 earnings per share for the quarter, beating the consensus estimate of $0.397 by $0.053.
Is Hinge Health, Inc. Class A overvalued?
According to Wall Street analysts Hinge Health, Inc. Class A’s price is currently Undervalued.
Does Hinge Health, Inc. Class A pay dividends?
Hinge Health, Inc. Class A does not currently pay dividends.
What is Hinge Health, Inc. Class A’s EPS estimate?
Hinge Health, Inc. Class A’s EPS estimate is 0.62.
How many shares outstanding does Hinge Health, Inc. Class A have?
Hinge Health, Inc. Class A has 54,655,926 shares outstanding.
What happened to Hinge Health, Inc. Class A’s price movement after its last earnings report?
Hinge Health, Inc. Class A reported an EPS of $0.45 in its last earnings report, beating expectations of $0.397. Following the earnings report the stock price went up 10.231%.
Which hedge fund is a major shareholder of Hinge Health, Inc. Class A?
Currently, no hedge funds are holding shares in HNGE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Hinge Health, Inc. Class A Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$87.64 (17.94% Upside)
$87.64 (17.94% Upside)
Blogger Sentiment
Bullish
HNGE Sentiment 83%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $212.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 2.2%
Last 30 Days ▲ 2.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
61.61%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
2.28%
Trailing 12-Months
Company Description
Hinge Health, Inc. Class A
Established in 2012 and headquartered in San Francisco, California, Hinge Health, Inc. creates specialized healthcare software solutions for musculoskeletal and joint health. Their advanced platform is designed to comprehensively manage a spectrum of needs, including general musculoskeletal care, acute injuries, persistent chronic pain, and post-operative rehabilitation. Furthermore, the company provides essential administrative and operational assistance.
HNGE Company Deck
HNGE Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational and financial momentum: a material revenue beat, double-digit growth in billings, substantial margin expansion, strong free cash flow, raised full-year guidance, rapid client uptake of the new migraine program following FDA clearance, and expanding commercial traction (including SMB and Hinge Select). Headwinds and risks include limited near-term revenue from migraine (meaningful benefit expected in 2027), concentration of new bookings in the back half of the year, continued device-related cost pressures as Enso distribution scales, and a deliberate decision to forgo the CMS ACCESS program. Overall, the positives (robust growth, margin expansion, guidance raise, product and commercial wins) substantially outweigh the near-term lowlights and risks.View all HNGE earnings summariesHNGE Stock 12 Month Forecast
Average Price Target
$87.64
▲(17.94% Upside)
Technical Analysis
Ownership Overview
8.47% Insiders
19.52% Mutual Funds
0.43% Other Institutional Investors
58.90% Public Companies and
Individual Investors